Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Spago Nanomedical

0,11 SEK

-1,32 %

Mindre end 1K følgere

SPAGO

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
-1,32 %
-52,10 %
-49,01 %
-17,88 %
-19,35 %
-20,56 %
-76,56 %
-97,58 %
-98,61 %

Spago Nanomedical is active in biotechnology. The company develops nanomedicine for the diagnosis and treatment of life-threatening diseases. The company's main activities are focused on developing a cancer-selective contrast agent for magnetic resonance imaging (MRI), as well as a product for radionuclide treatment of cancer. Both of these projects are based on proprietary nanomaterials. The largest operations are in the Nordic market, with the headquarters located in Lund.

Læs mere
Markedsværdi
74,1 mio. SEK
Aktieomsætning
85,22 t SEK
Omsætning
1,91 mio.
EBIT %
-1.764,92 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Pressemeddelelse7.11.2025, 07.50

The subscription period in Spago Nanomedical’s rights issue begins today

Spago Nanomedical
Pressemeddelelse6.11.2025, 09.00

Spago Nanomedical publishes information document in connection with forthcoming rights issue

Spago Nanomedical
Pressemeddelelse31.10.2025, 07.02

BioStock: Spago: "We are really encouraged by how the trial is progressing"

Spago Nanomedical

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse29.10.2025, 15.21

DNB Carnegie Access: Spago Nanomedical: Raising capital – Q3 review

Spago Nanomedical
Selskabsmeddelelse29.10.2025, 07.40

Spago Nanomedical resolves on a rights issue of approximately SEK 25 million to advance Tumorad

Spago Nanomedical
Selskabsmeddelelse29.10.2025, 07.00

Spago Nanomedical interim report January-September 2025

Spago Nanomedical
Pressemeddelelse16.10.2025, 07.24

BioStock: Spago’s CEO comments on Proof-of-Concept milestone

Spago Nanomedical
Pressemeddelelse15.10.2025, 11.10

DNB Carnegie Access: Spago Nanomedical: Intervju - Positiv utveckling för Tumorad

Spago Nanomedical
Pressemeddelelse15.10.2025, 06.27

DNB Carnegie Access: Spago Nanomedical: Cleared for a higher dose, noting encouraging uptake

Spago Nanomedical
Selskabsmeddelelse14.10.2025, 09.33

Visible tumor uptake and recommended dose increase in Spago Nanomedicals's Phase I/IIa study Tumorad-01

Spago Nanomedical
Pressemeddelelse2.9.2025, 17.24

DNB Carnegie Access: Spago Nanomedical: Highlights from DNB Carnegie’s Micro & Small Cap Day

Spago Nanomedical
Pressemeddelelse20.8.2025, 14.30

DNB Carnegie Access: Spago Nanomedical: Next dose evaluation approaching – Q2 review

Spago Nanomedical
Selskabsmeddelelse20.8.2025, 06.00

Spago Nanomedical interim report January-June, 2025

Spago Nanomedical
Pressemeddelelse9.6.2025, 08.27

BioStock: Spago’s phase I/IIa cancer study on track for 2025 completion

Spago Nanomedical
Pressemeddelelse5.6.2025, 07.55

DNB Carnegie Access: Spago Nanomedical: Intervju - Närmar sig viktiga resultat

Spago Nanomedical
Pressemeddelelse3.6.2025, 10.04

DNB Carnegie Access: Spago Nanomedical: DMC gives green light to proceed

Spago Nanomedical
Pressemeddelelse3.6.2025, 06.00

Spago Nanomedical continues patient recruitment in the phase I/IIa study Tumorad-01 as planned after DMC recommendation

Spago Nanomedical
Selskabsmeddelelse14.5.2025, 12.25

Bulletin from the 2025 Annual General Meeting of Spago Nanomedical AB

Spago Nanomedical
Pressemeddelelse8.5.2025, 13.52

Carnegie Access: Spago Nanomedical: Making steady progress in the Tumorad study – Q1(25) review

Spago Nanomedical
Selskabsmeddelelse7.5.2025, 06.00

Spago Nanomedical interim report January-March, 2025

Spago Nanomedical
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.